C M Tambe

Tata Memorial Centre, Mumbai, Mahārāshtra, India

Are you C M Tambe?

Claim your profile

Publications (8)8.63 Total impact

  • Fuel and Energy Abstracts 01/2011; 81(2).
  • Radiotherapy and Oncology - RADIOTHER ONCOL. 01/2011; 99.
  • [show abstract] [hide abstract]
    ABSTRACT: The treatment of patients with synchronous bilateral breast cancer is a challenge. We present a report of dosimetric data of patients with bilateral chest walls as the target treated with electron arc therapy. Ten consecutive patients who had undergone electron arc therapy to the bilateral chest wall for breast cancer were analysed. After positioning and immobilisation, patients underwent computed tomography scans from the neck to the upper abdomen. Electron arc plans were generated using the PLATO RTS (V1.8.2 Nucletron) treatment planning system. Electron energy was chosen depending upon the depth and thickness of the planning target volume (PTV). For all patients, the arc angle ranged between 80 and 280° (start angle 80°, stop angle 280°). The homogeneity index, coverage index and doses to organs at risk were evaluated. The patient-specific output factor and thermoluminescence dosimetry (TLD) measurements were carried out for all patients. The total planned dose to the PTV was 50Gy/25 fractions/5 weeks. The mean PTV (± standard deviation) was 568.9 (±116)cm(3). The mean PTV coverage was 89 (±5.8)% of the prescribed dose. For the right lung, the mean values of D(1) and D(10) were 46 (±7.6) and 30 (±9)Gy, respectively. For the left lung, the mean values of D(1) and D(10) were 45 (±7) and 27 (±8)Gy, respectively. For the heart, the mean values of D(1), D(5) and D(10) were 21 (±15), 13.5 (±12) and 9 (±9)Gy, respectively. The mean values of TLD at various pre-specified locations on the chest wall surface were 1.84, 1.82, 1.82, 1.89 and 1.78Gy, respectively The electron arc technique for treating the bilateral chest wall is a feasible and pragmatic technique. This technique has the twin advantages of adequate coverage of the target volume and sparing of adjacent normal structures. However, compared with other techniques, it needs a firm quality assurance protocol for dosimetry and treatment delivery.
    Clinical Oncology 12/2010; 23(3):216-22. · 2.86 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Purpose: On‐board mega voltage computed tomography (MVCT) detectors of a Helical Tomotherapy™ (HT) machine are routinely used for imaging and dosimetric purpose. First objective of this study was to estimate dosimetric and general capability (TomoImage registration, reconstruction, spatial resolution, artifacts free image and dose during TomoImage) of MVCT detectors. Second objective was to investigate system dosimetric stability (output and energy) of HT after major repairs. Methods and Materials: The lateral beam profiles were first measured in water at a depth of 1.5 cm with an A1SL (0.05 CC) ion chamber and later with the MVCT detectors for 5 cm jaw width with source to axis distance (SAD) of 85 cm. After a period of eight months, due to degraded image quality and gas leakage with the detector mechanism, the MVCT detectors were replaced. Due to frequent fluctuations in output and energy, the target was also replaced within the same period. Fixedgantry/ fixed‐couch measurements were made daily to investigate system stability. Static gantry output and energy measurements were measured with the manufacturer supplied and the independent (third party) dosimeters. Central axis depth dose (CADD) was measured and compared. The surface dose was also estimated. Thermoluminescense dosimeters (TLDs) were used subsequently. Results: The spatial resolution of MVCT detectors was optimal and the dose during TomoImage was 2 cGy. The results of lateral beam profiles showed an excellent agreement between the two normalized plots. The HT system has maintained its calibration to within ± 2% and energy to within ± 1.5% over the initial twelve months period. CADD measured with three dosimeters showed good agreement with each other. Conclusion: Based on the consistency in the lateral beam profile shape, the on‐board detectors proved to be a viable dosimetric quality assurance tool for HT. Tomotherapy output and energy was found stable after major repairs.
    Medical Physics 05/2009; 36(6):2540-2540. · 2.91 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The purpose of this work was to estimate skin dose for the patients treated with tomotherapy using metal oxide semiconductor field-effect transistors (MOSFETs) and thermoluminescent dosimeters (TLDs). In vivo measurements were performed for two head and neck patients treated with tomotherapy and compared to TLD measurements. The measurements were subsequently carried out for five days to estimate the inter-fraction deviations in MOSFET measurements. The variation between skin dose measured with MOSFET and TLD for first patient was 2.2%. Similarly, the variation of 2.3% was observed between skin dose measured with MOSFET and TLD for second patient. The tomotherapy treatment planning system overestimated the skin dose as much as by 10-12% when compared to both MOSFET and TLD. However, the MOSFET measured patient skin doses also had good reproducibility, with inter-fraction deviations ranging from 1% to 1.4%. MOSFETs may be used as a viable dosimeter for measuring skin dose in areas where the treatment planning system may not be accurate.
    Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine 04/2009; 67(9):1683-5. · 1.09 Impact Factor
  • Fuel and Energy Abstracts 01/2009; 75(3).
  • [show abstract] [hide abstract]
    ABSTRACT: A new model of the telecobalt unit (TCU), Theratron Equinox-80, (MDS Nordion, Canada) equipped with a single 60 degree motorized wedge (MW), four universal wedges (UW) for 15 degrees, 30 degrees, 45 degrees and 60 degrees have been evaluated. MW was commissioned in Eclipse (Varian, Palo Alto, USA) 3D treatment planning system (TPS). The profiles and central axis depth doses (CADD) were measured with Wellhofer blue water phantom for MW and the measured data was commissioned in Eclipse. These profiles and CADD for MW were compared with UW in a homogeneous phantom generated in Eclipse for various field sizes. The dose was also calculated in the same phantom at 10 cm depth. For the particular MW angle and the respective open and MW beam weights, the dose was measured for a field size of 10 cm x 10 cm in a MEDTEC water phantom at 10 cm depth with a 0.13 cc thimble ion chamber (Scanditronix Wellhofer, Uppsala, Sweden) and a NE electrometer (Nuclear Enterprises, UK). Measured dose with ion chamber was compared with the TPS calculated dose. MW angle verification was also done on the Equinox for four angles (15 degrees, 30 degrees, 45 degrees and 60 degrees). The variation in measured and calculated dose at 10 cm depth was within 2%. The measured and the calculated wedge angles were in good agreement within 2 degrees. The motorized wedges were successfully commissioned in Eclipse for four wedge angles.
    Australasian physical & engineering sciences in medicine / supported by the Australasian College of Physical Scientists in Medicine and the Australasian Association of Physical Sciences in Medicine 07/2007; 30(2):127-34. · 0.89 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Purpose of this study was to report in a together our experience of using ion chambers, TLD, MOSFET and EDR2 film for dosimetric verification of IMRT plans delivered with dynamic multileaf collimator (DMLC). Two ion chambers (0.6 and 0.13 CC) were used. All measurements were performed with a 6MV photon beam on a Varian Clinac 6EX LINAC equipped with a Millennium MLC. All measurements were additionally carried out with (LiF:Mg,TI) TLD chips. Five MOSFET detectors were also irradiated. EDR2 films were used to measure coronal planar dose for 10 patients. Measurements were carried out simultaneously for cumulative fields at central axis and at off-axis at isocenter plane (+/- 1, and +/- 2 cm). The mean percentage variation between measured cumulative central axis dose with 0.6 cc ion chamber and calculated dose with TPS was -1.4% (SD 3.2). The mean percentage variation between measured cumulative absolute central axis dose with 0.13 cc ion chamber and calculated dose with TPS was -0.6% (SD 1.9). The mean percentage variation between measured central axis dose with TLD and calculated dose with TPS was -1.8% (SD 2.9). A variation of less than 5% was found between measured off-axis doses with TLD and calculated dose with TPS. For all the cases, MOSFET agreed within +/- 5%. A good agreement was found between measured and calculated isodoses. Both ion chambers (0.6 CC and 0.13 CC) were found in good agreement with calculated dose with TPS.
    Australasian physical & engineering sciences in medicine / supported by the Australasian College of Physical Scientists in Medicine and the Australasian Association of Physical Sciences in Medicine 04/2007; 30(1):25-32. · 0.89 Impact Factor